Novartis Investigative Site

Torrance, California 90509-2910

0 studies enrolling now · 20 studies all time

What they study most

Acute Decompensated Heart Failure, Age Related Macular Degeneration (AMD), Asthma, Atherosclerosis, COVID-19 Pneumonia, Impaired Respiratory Function, Cardiovascular Disease, Cardiovascular Disease and Lipoprotein(a), Chronic Heart Failure (CHF), Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Pulmonary Disease (COPD) With Cachexia, Congestive Heart Failure

Studies at this site

• Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction — Completed
• Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema — Completed
• Study of Efficacy and Safety of MAS825 in Patients With COVID-19 — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Study of Efficacy of PEAR-004 in Schizophrenia — Completed
• A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD) — Completed
• Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD) — Completed
• Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD) — Completed
• Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis — Completed
• Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents — Completed
• BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia — Completed
• A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation. — Completed
• Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients — Completed
• Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early
• Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure — Completed
• Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) — Completed